Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Exploring future hair loss treatments, including immunosuppressants for hair transplants and hair cloning, with a focus on leveraging research from other medical fields. Current treatments like finasteride and minoxidil are effective for most, but there's a call for more funding and innovation in the hair loss industry.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. The user is considering using these alongside Pyrilutamide 0.9%.

The user shared progress pictures showing improvement in hair loss using oral finasteride and topical minoxidil. Another user suggested using dutasteride for better results.

People discuss hair loss treatments like minoxidil, finasteride, and dutasteride, sharing experiences and side effects. Opinions vary on combining treatments, with some skeptical and others reporting success.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

The user is experiencing an allergic reaction to propylene glycol in Kirkland minoxidil and is considering switching to a foam version or a low-PG minoxidil solution. They are also contemplating oral minoxidil but are concerned about its long-term safety.

Using topical finasteride 0.1%, minoxidil 5%, and melatonin for 7 months reduced hair loss significantly, with increased libido and decreased stress tolerance. The user applies the solution once daily, uses nizoral twice weekly, and takes vitamin D and ZMA supplements.

The conversation discusses using CB0301/Clascoterone as a potential treatment for hair loss, especially for those experiencing side effects from finasteride and dutasteride. The user currently uses oral minoxidil and considers combining it with other treatments like kx826, DHT blocker supplements, and 2% Nizoral shampoo.

The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.

The conversation is about a user whose insurance switched their prescription from finasteride to dutasteride, and they are considering whether to appeal the decision or continue with dutasteride. Other users suggest that both medications are affordable without insurance and that dutasteride may be more effective long-term.

Minoxidil is criticized for being inconvenient and ineffective compared to finasteride, with some users experiencing issues like flaking and greasy hair. Alternatives like adenosine are suggested, and the effectiveness of minoxidil can be improved with tretinoin and dietary changes.

The user reported improved hair quality and faster growth after switching from finasteride and topical minoxidil to dutasteride and oral minoxidil, despite experiencing significant shedding. They take separate pills daily and are optimistic about future progress.

The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

Nanoxidil is discussed as a potential alternative to Minoxidil for hair loss, with some users reporting better results and improved hair strength. However, concerns about its lack of FDA approval and potential scalp dryness are noted.

A user is attempting to reformulate a topical gel using PP-405 for hair loss, aiming to enhance its effectiveness with additional compounds. They discuss the potential of PP-405 compared to other treatments like Minoxidil and GT20029, and emphasize the importance of proper formulation for efficacy.

The user has been using finasteride (1 mg, three times a week) for a year and is considering adding oral minoxidil or increasing finasteride dosage, while also taking enclomiphene. They did not experience significant shedding with finasteride, but are concerned about potential shedding with new treatments.

The conversation discusses using minoxidil 5% and finasteride 1.25mg daily for hair loss, with the user experiencing monthly shedding and a slight decrease in sex drive as a side effect. The user also mentions using a shampoo with piroctone olamine for seborrheic dermatitis and considers oral minoxidil to reduce scalp irritation.

The conversation is about disappointment in the lack of new hair loss cures, with discussions on treatments like finasteride, minoxidil, and hair transplants. Some users express hope for future advancements, while others debate the effectiveness and side effects of current treatments.

Finding finasteride without a prescription in Europe, with users suggesting pharmacies like Greeno.ro and Farmacia en Andorra, and discussing online services like dokteronline.com for consultations. Some users also mention alternatives like making capsules from powder or using telehealth services for prescriptions.

The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

Piroctone olamine may be more effective and gentler than ketoconazole for dandruff and itchiness. Users report better results with piroctone olamine, but it is less available in the US.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

There is concern about a potential ban on finasteride in the EU, but many believe it is unlikely unless serious side effects are found. Users rely on finasteride for hair loss and other health benefits, and a petition has been created to oppose any restrictions.

The user is considering switching their hair loss routine from taking finasteride daily to a combination of finasteride six times a week and dutasteride once a week. They are seeking advice on this potential change.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.